Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Valeant psoriasis drug...

    Valeant psoriasis drug suicide risk hard to assess: FDA

    Written by savita thakur thakur Published On 2016-07-16T13:33:00+05:30  |  Updated On 16 July 2016 1:33 PM IST
    Valeant psoriasis drug suicide risk hard to assess: FDA

    Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, according to a preliminary review by the U.S. Food and Drug Administration published.


    The review comes two days ahead of a meeting of outside experts who will advise the FDA on whether the drug should be approved. The agency is not obliged to follow the advice of its advisory panels but typically does so.


    In clinical trials of the drug, brodalumab, there were six suicides across all programs: four in psoriasis studies, one in a rheumatoid arthritis study and one in a psoriatic arthritis study.


    "We have uncertainty about whether the signal for completed suicide is a risk related to brodalumab treatment," FDA reviewers said. "From the available data, we cannot conclude whether or not suicide is a drug-related risk."


    If approved, brodalumab has the potential to be used in a large number of patients in the United States and likely prescribed by a doctor that may not be familiar with screening for and diagnosing suicidal thinking and behavior, the reviewers said.


    There are several risk management options that could provide some assurance that doctors and patients understand the safe use conditions of taking the drug.


    "However, no risk management strategy will completely eliminate the risk" they said.


    Brodalumab, was initially developed by AstraZeneca Plc and Amgen Inc. In May, 2015, Amgen withdrew from the partnership after trials revealed the potential suicide risk.


    AstraZeneca subsequently licensed global rights to the drug to Valeant, whose fortunes have plummeted over the past year amid criticism of its high drug prices and suspect relationship with a specialty pharmacy.


    AstraZeneca recently terminated Valeant's license to market brodalumab in Europe and signed an exclusive license instead with Denmark's LEO Pharma.


    Before the trial results, AstraZeneca said brodalumab could generate annual sales of up to $1.5 billion a year. David Maris, an analyst at Wells Fargo, recently projected it would, if approved, generate just $250 million by 2020.


    "Given the drug's safety profile, we expect a challenging commercial launch," he said in a research report.


    Brodalumab is known as an interleukin-17 inhibitor. Other drugs in the same class include Novartis AG's Cosentyx and Eli Lilly & Co's Taltz.


    The drug would also compete with Amgen's Enbrel and AbbVie's Humira.

    AbbVieAmgenapprovedAstraZenecabrodalumab treatmentDavid MarisEli Lillyhigh drug pricesHumiraNovartispsoriasis drugpsoriatic arthritisrheumatoid arthritisskin disorder psoriasissuicide riskUS Food & Drug AdministrationUSFDAValeant
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok